Algert Global LLC Raises Holdings in AMNEAL PHARMACEUTICALS, INC. $AMRX

Key Points

• Algert Global LLC increased its stake in Amneal Pharmaceuticals by 25.7% in Q1, now holding approximately 560,783 shares valued at $4.7 million.
• Institutional investors own 31.82% of Amneal Pharmaceuticals, with notable increases in holdings by Raymond James Financial and Russell Investments Group.
• Amneal Pharmaceuticals' stock is currently priced at $9.26, and despite an EPS of $0.23 that beat estimates, it has a high price-to-earnings ratio of 926.93.

Algert Global LLC grew its holdings in AMNEAL PHARMACEUTICALS, INC. (NASDAQ:AMRX - Free Report) by 25.7% in the 1st quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 560,783 shares of the company's stock after acquiring an additional 114,788 shares during the quarter. Algert Global LLC owned 0.18% of AMNEAL PHARMACEUTICALS worth $4,699,000 at the end of the most recent reporting period.

Several other institutional investors have also added to or reduced their stakes in AMRX. Sei Investments Co. raised its stake in shares of AMNEAL PHARMACEUTICALS by 0.4% in the first quarter. Sei Investments Co. now owns 340,816 shares of the company's stock worth $2,710,000 after purchasing an additional 1,355 shares during the last quarter. Amalgamated Bank raised its position in AMNEAL PHARMACEUTICALS by 33.0% during the first quarter. Amalgamated Bank now owns 5,511 shares of the company's stock valued at $46,000 after acquiring an additional 1,367 shares in the last quarter. GF Fund Management CO. LTD. raised its position in AMNEAL PHARMACEUTICALS by 21.9% during the first quarter. GF Fund Management CO. LTD. now owns 7,934 shares of the company's stock valued at $66,000 after acquiring an additional 1,428 shares in the last quarter. Xponance Inc. raised its position in AMNEAL PHARMACEUTICALS by 16.1% during the first quarter. Xponance Inc. now owns 13,183 shares of the company's stock valued at $110,000 after acquiring an additional 1,828 shares in the last quarter. Finally, MetLife Investment Management LLC raised its position in AMNEAL PHARMACEUTICALS by 2.5% during the fourth quarter. MetLife Investment Management LLC now owns 94,639 shares of the company's stock valued at $750,000 after acquiring an additional 2,297 shares in the last quarter. Institutional investors and hedge funds own 31.82% of the company's stock.

AMNEAL PHARMACEUTICALS Trading Up 1.3%

NASDAQ AMRX traded up $0.12 on Thursday, reaching $9.53. 1,258,125 shares of the company were exchanged, compared to its average volume of 1,672,365. The business's fifty day moving average price is $8.34 and its 200 day moving average price is $8.00. The stock has a market capitalization of $2.99 billion, a P/E ratio of 953.95 and a beta of 1.11. AMNEAL PHARMACEUTICALS, INC. has a fifty-two week low of $6.68 and a fifty-two week high of $9.62.

AMNEAL PHARMACEUTICALS (NASDAQ:AMRX - Get Free Report) last released its quarterly earnings data on Tuesday, August 5th. The company reported $0.23 earnings per share for the quarter, topping analysts' consensus estimates of $0.17 by $0.06. AMNEAL PHARMACEUTICALS had a negative return on equity of 189.49% and a net margin of 0.12%. AMNEAL PHARMACEUTICALS has set its FY 2025 guidance at 0.700-0.750 EPS. Equities research analysts forecast that AMNEAL PHARMACEUTICALS, INC. will post 0.53 earnings per share for the current year.

Analyst Ratings Changes

A number of research firms have recently commented on AMRX. Wall Street Zen cut AMNEAL PHARMACEUTICALS from a "strong-buy" rating to a "buy" rating in a research report on Tuesday, May 13th. The Goldman Sachs Group began coverage on AMNEAL PHARMACEUTICALS in a research report on Friday, June 6th. They issued a "buy" rating and a $12.00 price objective for the company. Five analysts have rated the stock with a Buy rating, Based on data from MarketBeat, the company has a consensus rating of "Buy" and an average price target of $11.60.

Insider Activity

In other news, EVP Nikita Shah sold 71,694 shares of the company's stock in a transaction on Thursday, August 14th. The stock was sold at an average price of $9.29, for a total value of $666,037.26. Following the transaction, the executive vice president owned 267,235 shares of the company's stock, valued at $2,482,613.15. This represents a 21.15% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, EVP Jason B. Daly sold 22,000 shares of the company's stock in a transaction on Tuesday, August 12th. The shares were sold at an average price of $9.05, for a total value of $199,100.00. Following the completion of the transaction, the executive vice president directly owned 10,606 shares in the company, valued at approximately $95,984.30. This trade represents a 67.47% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 177,130 shares of company stock valued at $1,619,733 in the last quarter. Insiders own 26.56% of the company's stock.

AMNEAL PHARMACEUTICALS Profile

Amneal Pharmaceuticals, Inc, together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products.